Active Specific Immunotherapy of Colorectal Cancer

  • H. C. HooverJr.
  • M. G. HannaJr.


In spite of improvements in surgical approaches, colorectal cancer patients with transmural extension of tumor and/or metastases to regional lymph nodes still have 5-year survival rates of only 20%–50% when treated by operative resection alone. Adjuvant radiation therapy can lower the incidence of local recurrence in rectal cancer, but does not control systemic metastasis. Toxicity and drug resistance continue to limit the usefulness of chemotherapy, although some benefit is suggested in a recent study (Wolmark et al. 1988).


Rectal Cancer Patient Colon Cancer Patient Autologous Tumor Cell Tumor Cell Vaccine Active Specific Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berd D, Maguire HC, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577PubMedGoogle Scholar
  2. Dye ES, North RJ (1981) T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med 154:1033–1042, 1981PubMedCrossRefGoogle Scholar
  3. Hanna MG, Brandhorst JS, Peters LC (1979) Active specific immunotherapy of residual micrometastasis: an evaluation of sources, doses and ratios of BCG with tumor cells. Cancer Immunol Immunother 7:165–173CrossRefGoogle Scholar
  4. Haspell MV, Hoover HC, McCabe RP et al. (1984) Human colon cancer; generation of tumor-specific human monoclonal antibodies. Proc Am Assoc Cancer Res 25:236Google Scholar
  5. Hoover HC Jr, Surdyke M, Dangel R et al. (1984) Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: bacillus Calmette-Guerin vaccine. Cancer Res 44:1671–1676PubMedGoogle Scholar
  6. Hoover HC, Surdyke MG, Dangel RB et al. (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55:1263–1243CrossRefGoogle Scholar
  7. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 55:1063–1074CrossRefGoogle Scholar
  8. Peters LC, Brandhorst JS, Hanna MG Jr (1979) Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 39:1353–1360PubMedGoogle Scholar
  9. Peters LC, Hanna MG Jr (1980) Active-specific immunotherapy of established micrometastasis: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst 64:1521–1525PubMedGoogle Scholar
  10. Wolmark N, Fisher B, Rockette H et al. (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP Protocol C-01. J Natl Can Inst 80:30–36CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • H. C. HooverJr.
    • 1
  • M. G. HannaJr.
    • 2
  1. 1.Surgical Oncology Research Massachusetts General Hospital BostonUSA
  2. 2.Bionetics Research Inc.RockvilleUSA

Personalised recommendations